Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cagrilintide in subjects with obesity or overweight
NCT02958085Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Nov 2016
- Primary completion
- Jan 2018
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in obesity comparing Cagrilintide with Placebo (2 arms). Primary endpoint: Number of treatment emergent adverse events. Started Nov 2016; status: completed.
02
Drugs
cagrilintide
03
Conditions
obesity
Beyond the preview
Go deeper on NCT02958085.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02958085.